Regencell Bioscience Holdings Limited (NASDAQ:RGC – Get Free Report) rose 8.7% during trading on Tuesday. The company traded as high as $7.06 and last traded at $7.3490. Approximately 101,532 shares were traded during mid-day trading, a decline of 66% from the average daily volume of 299,003 shares. The stock had previously closed at $6.76.
Wall Street Analysts Forecast Growth
Several brokerages recently weighed in on RGC. Weiss Ratings restated a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Monday, September 21st. Wall Street Zen lowered Regencell Bioscience from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. One analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock has an average rating of “Sell”.
Get Our Latest Report on Regencell Bioscience
Regencell Bioscience Stock Performance
The company has a 50 day moving average of $6.70 and a two-hundred day moving average of $17.98.
Regencell Bioscience (NASDAQ:RGC – Get Free Report) last announced its quarterly earnings data on Wednesday, October 7th. The company reported ($0.01) EPS for the quarter.
Institutional Trading of Regencell Bioscience
An institutional investor recently bought a new stake in Regencell Bioscience stock. Amundi purchased a new stake in Regencell Bioscience Holdings Limited (NASDAQ:RGC – Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 8,595 shares of the company’s stock, valued at approximately $219,000. 0.13% of the stock is currently owned by institutional investors.
About Regencell Bioscience
Regencell Bioscience Holdings Limited is a Hong Kong-based biotechnology company focused on developing traditional Chinese medicine (TCM) formulations for neurological and neurocognitive disorders. Its research has primarily targeted attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD), conditions for which the company is exploring TCM-based therapeutic approaches.
The company’s development activities center on proprietary herbal formulations and related treatment protocols.
Featured Stories
- Five stocks we like better than Regencell Bioscience
- Whirlpool’s Stock Collapse Raises a Bigger Question About Its Recovery Potential
- Analysts Turn Bullish on Meta Platforms Despite Post-Earnings Fall
- Approaching Earnings Season, Are Pure Play Quantum Stocks Still a Good Bet?
- Lockheed Martin’s F-35 Deal Could Change How Wall Street Values the Stock
Receive News & Ratings for Regencell Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regencell Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
